Biological Psychiatry-Cognitive Neuroscience and Neuroimaging最新文献

{"title":"Comparing Neural Correlates of Consciousness: From Psychedelics to Hypnosis and Meditation","authors":"Flora Moujaes ,&nbsp;Nathalie M. Rieser ,&nbsp;Christophe Phillips ,&nbsp;Nuno M.P. de Matos ,&nbsp;Mike Brügger ,&nbsp;Patricia Dürler ,&nbsp;Lukasz Smigielski ,&nbsp;Philipp Stämpfli ,&nbsp;Erich Seifritz ,&nbsp;Franz X. Vollenweider ,&nbsp;Alan Anticevic ,&nbsp;Katrin H. Preller","doi":"10.1016/j.bpsc.2023.07.003","DOIUrl":"10.1016/j.bpsc.2023.07.003","url":null,"abstract":"<div><h3>Background</h3><p>Pharmacological and nonpharmacological methods of inducing altered states of consciousness (ASCs) are becoming increasingly relevant in the treatment of psychiatric disorders. While comparisons between them are often drawn, to date no study has directly compared their neural correlates.</p></div><div><h3>Methods</h3><p>To address this knowledge gap, we directly compared 2 pharmacological methods (psilocybin 0.2 mg/kg orally [<em>n</em> = 23] and lysergic acid diethylamide [LSD] 100 μg orally [<em>n</em> = 25]) and 2 nonpharmacological methods (hypnosis [<em>n</em> = 30] and meditation [<em>n</em> = 29]) using resting-state functional connectivity magnetic resonance imaging and assessed the predictive value of the data using a machine learning approach.</p></div><div><h3>Results</h3><p>We found that 1) no network reached significance in all 4 ASC methods; 2) pharmacological and nonpharmacological interventions of inducing ASCs showed distinct connectivity patterns that were predictive at the individual level; 3) hypnosis and meditation showed differences in functional connectivity when compared directly and also drove distinct differences when jointly compared with the pharmacological ASC interventions; and 4) psilocybin and LSD showed no differences in functional connectivity when directly compared with each other, but they did show distinct behavioral-neural relationships.</p></div><div><h3>Conclusions</h3><p>Overall, these results extend our understanding of the mechanisms of action of ASCs and highlight the importance of exploring how these effects can be leveraged in the treatment of psychiatric disorders.</p></div>","PeriodicalId":54231,"journal":{"name":"Biological Psychiatry-Cognitive Neuroscience and Neuroimaging","volume":"9 5","pages":"Pages 533-543"},"PeriodicalIF":5.9,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S245190222300174X/pdfft?md5=8d72c7d1af6faca3599cecf84a227553&pid=1-s2.0-S245190222300174X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10185332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychedelics and the Neurobiology of Meaningfulness","authors":"John H. Krystal ,&nbsp;Katrin H. Preller ,&nbsp;Philip R. Corlett ,&nbsp;Alan Anticevic ,&nbsp;Alfred P. Kaye","doi":"10.1016/j.bpsc.2023.09.003","DOIUrl":"10.1016/j.bpsc.2023.09.003","url":null,"abstract":"","PeriodicalId":54231,"journal":{"name":"Biological Psychiatry-Cognitive Neuroscience and Neuroimaging","volume":"9 5","pages":"Pages 462-463"},"PeriodicalIF":5.9,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41125221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Subscribers' Page","authors":"","doi":"10.1016/S2451-9022(24)00089-2","DOIUrl":"https://doi.org/10.1016/S2451-9022(24)00089-2","url":null,"abstract":"","PeriodicalId":54231,"journal":{"name":"Biological Psychiatry-Cognitive Neuroscience and Neuroimaging","volume":"9 5","pages":"Page A2"},"PeriodicalIF":5.9,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140843472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Guide for Authors","authors":"","doi":"10.1016/S2451-9022(24)00092-2","DOIUrl":"https://doi.org/10.1016/S2451-9022(24)00092-2","url":null,"abstract":"","PeriodicalId":54231,"journal":{"name":"Biological Psychiatry-Cognitive Neuroscience and Neuroimaging","volume":"9 5","pages":"Pages A5-A10"},"PeriodicalIF":5.9,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2451902224000922/pdfft?md5=4077950a16f73c9416fb431c7e19f104&pid=1-s2.0-S2451902224000922-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140843474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial Board Page","authors":"","doi":"10.1016/S2451-9022(24)00088-0","DOIUrl":"https://doi.org/10.1016/S2451-9022(24)00088-0","url":null,"abstract":"","PeriodicalId":54231,"journal":{"name":"Biological Psychiatry-Cognitive Neuroscience and Neuroimaging","volume":"9 5","pages":"Page A1"},"PeriodicalIF":5.9,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2451902224000880/pdfft?md5=ebcc676d5a029d4887f5110af9b14bdb&pid=1-s2.0-S2451902224000880-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140843471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microdosing Psychedelics: Current Evidence From Controlled Studies","authors":"Robin J. Murphy ,&nbsp;Suresh Muthukumaraswamy ,&nbsp;Harriet de Wit","doi":"10.1016/j.bpsc.2024.01.002","DOIUrl":"10.1016/j.bpsc.2024.01.002","url":null,"abstract":"<div><p>Taking regular low doses of psychedelic drugs (microdosing) is a practice that has drawn recent scientific and media attention for its potential psychotherapeutic effects. Yet, controlled studies evaluating this practice have lagged. Here, we review recent evidence focusing on studies that were conducted with rigorous experimental control. Studies conducted under laboratory settings using double-blind placebo-controlled procedures and investigator-supplied drug were compiled. The review includes demographic characteristics of participants and dependent measures such as physiological, behavioral, and subjective effects of the drugs. Review criteria were met by 14 studies, all of which involved acute or repeated low (5–20 μg) doses of lysergic acid diethylamide (LSD). Acute microdoses of LSD dose-dependently altered blood pressure, sleep, neural connectivity, social cognition, mood, and perception of pain and time. Perceptible drug effects were reported at doses of 10 to 20 μg but not 5 μg. No serious adverse effects were reported. Repeated doses of LSD did not alter mood or cognition on any of the measures studied. The findings suggest that low doses of LSD are safe and produce acute behavioral and neural effects in healthy adults. Further studies are warranted to extend these findings to patient samples and to other psychedelic drugs and to investigate microdosing as a potential pharmacological treatment for psychiatric disorders.</p></div>","PeriodicalId":54231,"journal":{"name":"Biological Psychiatry-Cognitive Neuroscience and Neuroimaging","volume":"9 5","pages":"Pages 500-511"},"PeriodicalIF":5.9,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2451902224000156/pdfft?md5=89812594a053ce6d2b9ead9cf1a08288&pid=1-s2.0-S2451902224000156-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139572386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expectancy Effects in Psychedelic Trials","authors":"Balázs Szigeti ,&nbsp;Boris D. Heifets","doi":"10.1016/j.bpsc.2024.02.004","DOIUrl":"10.1016/j.bpsc.2024.02.004","url":null,"abstract":"<div><p>Clinical trials of psychedelic compounds like psilocybin, lysergic acid diethylamide (LSD), and <em>N,N</em>-dimethyltrptamine (DMT) have forced a reconsideration of how nondrug factors, such as participant expectations, are measured and controlled in mental health research. As doses of these profoundly psychoactive substances increase, so does the difficulty in concealing the treatment condition in the classic double-blind, placebo-controlled trial design. As widespread public enthusiasm for the promise of psychedelic therapy grows, so do questions regarding whether and how much trial results are biased by positive expectancy. First, we review the key concepts related to expectancy and its measurement. Then, we review expectancy effects that have been reported in both micro- and macrodose psychedelic trials from the modern era. Finally, we consider expectancy as a discrete physiological process that can be independent of, or even interact with, the drug effect. Expectancy effects can be harnessed to improve treatment outcomes and can also be actively managed in controlled studies to enhance the rigor and generalizability of future psychedelic trials.</p></div>","PeriodicalId":54231,"journal":{"name":"Biological Psychiatry-Cognitive Neuroscience and Neuroimaging","volume":"9 5","pages":"Pages 512-521"},"PeriodicalIF":5.9,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139934697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Brief Historical Overview of Psychedelic Research","authors":"Mark A. Geyer","doi":"10.1016/j.bpsc.2023.11.003","DOIUrl":"10.1016/j.bpsc.2023.11.003","url":null,"abstract":"<div><p>Classical serotonergic psychedelics<span><span><span><span> such as lysergic acid diethylamide or the naturally occurring compounds </span>psilocybin and </span>mescaline<span> produce profound changes in mood, thought, intuition, sensory perception, the experience of time and space, and even the experience of self. Research examining psychedelic compounds has had a complex and turbulent evolution. Many cultures throughout the world have used psychedelic plants not only for mystical, ritualistic, or divinatory purposes but also for curing illnesses. Much of the genesis and progress of modern investigations into the effects and underlying mechanisms of action of psychedelics have been intertwined with studies of the neurotransmitter serotonin. Early hypotheses that serotonergic systems mediate psychedelic effects were supported initially by preclinical animal studies and subsequently confirmed by pharmacological studies in healthy humans. The use of psychedelic compounds as putative </span></span>psychotomimetics<span> that reproduce some features of naturally occurring psychotic disorders met with some limited success. More recent studies are exploring psychedelics as potential psychotherapeutic agents<span><span>. Recent indications that even 1 or 2 psychedelic treatments produce robust and sustained reductions in clinical </span>symptoms in a variety of psychiatric disorders have prompted an enormous resurgence of interest in the nature and mechanisms contributing to their effects.</span></span></span></p></div>","PeriodicalId":54231,"journal":{"name":"Biological Psychiatry-Cognitive Neuroscience and Neuroimaging","volume":"9 5","pages":"Pages 464-471"},"PeriodicalIF":5.9,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138435558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effective Connectivity of Thalamocortical Interactions Following d-Amphetamine, LSD, and MDMA Administration","authors":"Mihai Avram ,&nbsp;Felix Müller ,&nbsp;Katrin H. Preller ,&nbsp;Adeel Razi ,&nbsp;Helena Rogg ,&nbsp;Alexandra Korda ,&nbsp;Friederike Holze ,&nbsp;Patrick Vizeli ,&nbsp;Laura Ley ,&nbsp;Matthias E. Liechti ,&nbsp;Stefan Borgwardt","doi":"10.1016/j.bpsc.2023.07.010","DOIUrl":"10.1016/j.bpsc.2023.07.010","url":null,"abstract":"<div><h3>Background</h3><p>While the exploration of serotonergic psychedelics as psychiatric medicines deepens, so does the pressure to better understand how these compounds act on the brain.</p></div><div><h3>Methods</h3><p>We used a double-blind, placebo-controlled, crossover design and administered lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA), and d-amphetamine in 25 healthy participants. By using spectral dynamic causal modeling, we mapped substance-induced changes in effective connectivity between the thalamus and different cortex types (unimodal vs. transmodal) derived from a previous study with resting-state functional magnetic resonance imaging data. Due to the distinct pharmacological modes of action of the 3 substances, we were able to investigate specific effects mainly driven by different neurotransmitter systems on thalamocortical and corticothalamic interactions.</p></div><div><h3>Results</h3><p>Compared with placebo, all 3 substances increased the effective connectivity from the thalamus to specific unimodal cortices, whereas the influence of these cortices on the thalamus was reduced. These results indicate increased bottom-up and decreased top-down information flow between the thalamus and some unimodal cortices. However, for the amphetamines, we found the opposite effects when examining the effective connectivity with transmodal cortices, including parts of the salience network. Intriguingly, LSD increased the effective connectivity from the thalamus to both unimodal and transmodal cortices, indicating a breach in the hierarchical organization of ongoing brain activity.</p></div><div><h3>Conclusions</h3><p>The results advance our knowledge about the action of psychedelics on the brain and refine current models aiming to explain the underlying neurobiological processes.</p></div>","PeriodicalId":54231,"journal":{"name":"Biological Psychiatry-Cognitive Neuroscience and Neuroimaging","volume":"9 5","pages":"Pages 522-532"},"PeriodicalIF":5.9,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S245190222300191X/pdfft?md5=8722867a4a25c7da711de59cd5b008f8&pid=1-s2.0-S245190222300191X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9923469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychedelics in Medicine: Can Evidence Keep Up With Enthusiasm?","authors":"Harriet de Wit ,&nbsp;Friederike Holze ,&nbsp;Katrin H. Preller","doi":"10.1016/j.bpsc.2024.02.010","DOIUrl":"https://doi.org/10.1016/j.bpsc.2024.02.010","url":null,"abstract":"","PeriodicalId":54231,"journal":{"name":"Biological Psychiatry-Cognitive Neuroscience and Neuroimaging","volume":"9 5","pages":"Pages 460-461"},"PeriodicalIF":5.9,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140843476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}